Arcutis Raises 2026 Revenue Guidance on Zoryve Momentum and Pediatric Approval

What happened

Arcutis raised its full-year 2026 net product revenue guidance following a strong Q2, building on Zoryve's momentum that included the FDA approval for pediatric psoriasis down to age 2 and the submission of an infant atopic dermatitis sNDA. The Q1 seasonality headwind reversed as expected, with Q2 revenue re-accelerating sequentially, and operating cash flow remained positive despite increasing SG&A investment. The company also indicated potential new indications in the pipeline, hinting at broader franchise expansion. While the raised guidance signals confidence, it reflects a set of favorable but still-early developments, and execution risks around salesforce productivity and gross-to-net dynamics remain. The balance sheet has a moderate buffer with $224.3 million in cash and marketable securities as of March 31, 2026, but the minimum net product revenue covenant on its debt adds downside if growth stalls.

Implication

Investors should increase conviction in ARQT's scaled dermatology franchise if Q2 net product revenue exceeded $115 million and operating cash flow stayed positive, as those were preconditions for upside in the base case. However, the stock's valuation already reflects significant growth expectations, so the key is execution on the internal primary care/pediatrics sales force and conversion of expanded labels into sustainable prescription trends. The raised guidance reduces near-term covenant risk, but the minimum net product revenue covenant tied to internal projections remains a tail risk if demand decelerates. With the pediatric psoriasis approval now in hand, attention shifts to infant AD acceptance and pipeline advancement decisions in Q4 2026 and Q1 2027, which could provide additional catalysts. Aggressive investors may add on any pullback below $19, while conservative investors should wait for confirmation that Q2's revenue re-acceleration is not a one-quarter phenomenon.

Thesis delta

The previous thesis hinged on Q2 revenue re-acceleration and the June 29 pediatric psoriasis FDA decision. Both appear to have materialized with the raised guidance and approval, shifting the story from catalyst anticipation to execution. The core franchise scaling narrative is now better supported, but the stock likely already reflects these positives, so incremental upside depends on infant AD progress, pipeline optionality, and sustained prescription growth.